Table 16:
Cost Parameters
| Parameter | Cost, $ | Sources |
|---|---|---|
| Prenatal screening | ||
| eFTSa | 124.50 | Data from an Ontario hospital, 2018 |
| MSSb | 186.75 | Data from an Ontario hospital, 2018 |
| NIPTc | ||
| Trisomies 21, 18, and 13, and sex chromosome aneuploidies | 390 | Ministry of Health and Long-Term Care |
| Inclusion of 22q11.2 deletion | Extra 195 (Panorama) | LifeLabs Genetics112 |
| NT ultrasound (for 90% people for first-tier NIPT) | 59.85 | Ontario Schedule of Benefits113 |
| General assessment physician visit (e.g., to introduce prenatal screening) | 77.20 | Ontario Schedule of Benefits113 |
| Genetic counselling for trisomies 21, 18, and 13 | ||
| Positive NIPT result | 74.70 | Ontario Schedule of Benefits113 |
| Negative NIPT result | 37.65 | Ontario Schedule of Benefits113 |
| Additional counselling for sex chromosome aneuploidies and/or 22q11.2 deletion | 74.70 | Ontario Schedule of Benefits113 |
| Amniocentesis (total) | 586 | |
| Physician | 102 | Ontario Schedule of Benefits113 |
| Laboratory expenses, labour, and reagents | 484 | Lilley et al, 2017114 |
| Chorionic villus sampling (total) | 1,003 | |
| Physician | 153 | Ontario Schedule of Benefits113 |
| Laboratory expenses, labour, and reagents | 850 | Lilley et al, 2017114 |
| Post-test physician visit for pregnant people with positive screening test results (any strategy) | 74.70 | Ontario Schedule of Benefits113 |
| Physician visit for pregnant people with a confirmed affected fetus | 161.15 | Ontario Schedule of Benefits113 |
| Voluntary termination of pregnancy (total) | 1,308 | |
| Surgeon and anesthesiologist | 204 | Ontario Schedule of Benefits113 |
| Termination of pregnancy | 1,104 | Ontario Case Costing Initiative115 |
| Spontaneous pregnancy loss or diagnostic testing procedure-related pregnancy loss (total) | 658 | |
| Surgeon and anesthesiologist | 204 | Ontario Schedule of Benefits113 |
| Ambulatory care | 454 | Ontario Case Costing Initiative115 |
Abbreviations: eFTS, enhanced first-trimester screening; MSS, maternal serum screening (also known as quadruple screening); NIPT, noninvasive prenatal testing; NT, nuchal translucency.
a
eFTS includes pregnancy-associated plasma protein A, free β-human chorionic gonadotrophin, placental growth factor, α-fetoprotein, and NT ultrasound.
b
MSS (quadruple screening) includes α-fetoprotein, unconjugated estriol, free β-human chorionic gonadotrophin. and inhibin-A.
c
If NIPT fails for any reason, there are no additional costs for a repeat test. If the repeat (second) NIPT test also fails, there are no refunds for unsuccessful tests.